{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:38:14Z","timestamp":1791106694520,"version":"4.1.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,8,1]]},"DOI":"10.1210\/er.2001-2002","type":"journal-article","created":{"date-parts":[[2002,8,30]],"date-time":"2002-08-30T13:22:48Z","timestamp":1030713768000},"page":"508-516","source":"Crossref","is-referenced-by-count":334,"title":["II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women"],"prefix":"10.1210","volume":"23","author":[{"given":"Ann","family":"Cranney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Willan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zytaruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Osteoporosis Methodology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Osteoporosis Research Advisory Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"2019041121354030800_R1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2019041121354030800_R2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"Prevention of non vertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA"},{"key":"2019041121354030800_R3","first-page":"1535","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.","volume":"348","author":"Black","year":"1996","journal-title":"Fracture Intervention Trial Research Group Lancet"},{"issue":"Suppl 3","key":"2019041121354030800_R4","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/BF01623001","article-title":"Preclinical pharmacology of alendronate","volume":"3","author":"Rodan","year":"1993","journal-title":"Osteoporos Int"},{"key":"2019041121354030800_R5","author":"Mulrow","year":"1994"},{"key":"2019041121354030800_R6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"2019041121354030800_R7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"2019041121354030800_R8","first-page":"265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121354030800_R9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"key":"2019041121354030800_R10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2019041121354030800_R11","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2019041121354030800_R12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo controlled, randomized trial of effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study.","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporosis Int"},{"key":"2019041121354030800_R13","author":"Bonnick"},{"key":"2019041121354030800_R14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Alendronate reduces the risk of vertebral fractures in women without pre-existing vertebral fractures: results of the Fracture Intervention Trial.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2019041121354030800_R15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jamia.1994.95153434","article-title":"Developing optimal search strategies for detecting clinically sound strategies in MEDLINE.","volume":"1","author":"Haynes","year":"1994","journal-title":"J Am Med Info Assoc"},{"key":"2019041121354030800_R16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.","volume":"101","author":"Tucci","year":"1996","journal-title":"Am J Med"},{"key":"2019041121354030800_R17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"key":"2019041121354030800_R18","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1007\/BF01623004","article-title":"Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin","volume":"3","author":"Adami","year":"1993","journal-title":"Osteoporosis Int"},{"key":"2019041121354030800_R19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis.","volume":"2","author":"Fleiss","year":"1993","journal-title":"Stat Methods Med Res"},{"key":"2019041121354030800_R20","author":"Hedges","year":"1985"},{"key":"2019041121354030800_R21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(95)00400-9","article-title":"Sustained response to intravenous alendronate in postmenopausal osteoporosis.","volume":"17","author":"Vasikaran","year":"1995","journal-title":"Bone"},{"key":"2019041121354030800_R22","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.5650091121","article-title":"Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.","volume":"9","author":"Rossini","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2019041121354030800_R23","first-page":"1399","article-title":"The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.","volume":"76","author":"Harris","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121354030800_R24","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/BF01623003","article-title":"Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women","volume":"3","author":"Chesnut III","year":"1993","journal-title":"Osteoporosis Int"},{"key":"2019041121354030800_R25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2019041121354030800_R26","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial.","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121354030800_R27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2019041121354030800_R28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.","volume":"282","author":"Harris","year":"1999","journal-title":"J Am Med Assoc"},{"key":"2019041121354030800_R29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7326\/0003-4819-115-11-837","article-title":"Which fractures are associated with low appendicular mass in elderly women?","volume":"115","author":"Seeley","year":"1991","journal-title":"Ann Intern Med"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/23\/4\/508\/8860923\/edrv0508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T06:20:06Z","timestamp":1555050006000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/23\/4\/508\/2433272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,1]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,11,7]]},"published-print":{"date-parts":[[2002,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2001-2002","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,1]]}}}